IFEX/MESNEX KIT

LOE Approaching

ifosfamide

NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Alkylating Activity

Pharmacologic Class:

Alkylating Drug

Clinical Trials (5)

NCT06156410Phase 1Recruiting

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Started Oct 2023
30 enrolled
Ewing SarcomaOsteosarcomaSarcomas
NCT05364424Phase 1Completed

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Started Nov 2022
43 enrolled
Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04833114Phase 3Active Not Recruiting

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Started Apr 2021
306 enrolled
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
NCT04665765Phase 2Active Not Recruiting

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Started Jan 2021
NCT04154189Phase 2Completed

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Started Mar 2020
81 enrolled
Osteosarcoma